Chiglitazar for liver cirrhosis caused by fatty liver disease
Part of Digestive system, Hormones & metabolism clinical trials.
This trial tests a new pill, chiglitazar, to see if it can improve liver health in people with cirrhosis related to fatty liver disease. It aims to stop the disease from getting worse and prevent complications, and may benefit people with type 2 diabetes or obesity.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- Your doctor has confirmed you have cirrhosis (advanced liver scarring) related to fatty liver disease.
- You have either type 2 diabetes, obesity, or at least one other metabolic condition (like high blood pressure or high cholesterol).
- Your liver disease is not caused by hepatitis, heavy alcohol use, or other liver conditions.
- You have not had serious liver complications like fluid in the belly, bleeding, or liver cancer.
- You are willing to take a daily pill and have regular check-ups, including liver scans and blood tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is testing ways to prevent and treat liver scarring (fibrosis) caused by a condition called MAFLD, which is a buildup of fat in the liver. If you have this condition and some liver scarring, this trial may offer a chance to help manage it.
This trial tests a new oral medication, Chiglitazar, for people who have both type 2 diabetes and a fatty liver condition called MASH (fatty liver with inflammation and scarring). It aims to see if the drug can help improve liver health and diabetes control.
This study tests whether a new pill, chiglitazar, can help lower blood sugar when added to your current diabetes medicine (an SGLT-2 inhibitor). It may be an option if your blood sugar is still not well controlled.
This trial tests how the body processes saroglitazar in people with moderate liver impairment caused by cholestatic liver disease. The goal is to ensure the drug is safe and dosed correctly for this group.
This study tests an investigational combination tablet for diabetes. It looks at how food affects the drug and how the body handles it when taken multiple times.
This Phase 1 trial studies how saroglitazar magnesium works in people with liver scarring (cirrhosis) caused by a bile-flow problem. It helps doctors understand safety and how the body handles the medicine in this specific liver condition.
Hear when a new Metabolic Dysfunction-associated Fatty Liver Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.